Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki… - Journal of Medical …, 2023 - Taylor & Francis
Aims To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …
被引用次数：2 相关文章

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, P Saroccoa… - Journal of Medical …, 2023 - research.bangor.ac.uk
Aims To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …
[PDF] wustl.edu

[PDF][PDF] Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki, P Sarocco, J Wei… - 2023 - digitalcommons.wustl.edu
Aims: To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …
[PDF] researchgate.net

[PDF][PDF] Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki… - JOURNAL OF …, 2023 - researchgate.net
Aims: To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki… - Journal of Medical …, 2023 - scholars.uthscsa.edu
Aims: To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.

P Gebrehiwet, L Meng, SA Rudnicki… - Journal of Medical …, 2023 - europepmc.org
Aims To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki, P Sarocco, J Wei… - 2023 - pubmed.ncbi.nlm.nih.gov
Aims To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki… - Journal of Medical …, 2023 - pure.johnshopkins.edu
Aims: To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki… - Journal of Medical …, 2023 - profiles.wustl.edu
Aims: To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …
[PDF] researchgate.net

[PDF][PDF] Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

P Gebrehiwet, L Meng, SA Rudnicki… - JOURNAL OF …, 2023 - researchgate.net
Aims: To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …